Thursday, 29 June 2023
The results of a clinical trial have shown that a drug commonly used for patients with bleeding disorders has the potential to be used to lessen the side effects of blood-thinning drugs for patients who have experienced a stroke.
Researchers from the 糖心原创 and Oxford University Hospitals NHS Foundation Trust assessed the suitability of Desmopressin to be used in larger trials to help reduce the number of people who die or are disabled after intracerebral haemorrhage. The results from the DASH trial, which was funded by the (NIHR), have been published in The Lancet Neurology.
Approximately 3 million deaths each year are due to spontaneous intracerebral haemorrhage worldwide and there is currently no proven effective drug treatment. Researchers estimate that two-thirds of survivors are left dependent on others and a quarter of patients were taking antiplatelet drugs at the time of incident.
The results of the DASH trial are an important step towards assessing whether desmopressin might reduce the high risk of death or disability from intracerebral haemorrhage worldwide.
Patients from 10 hospitals across the UK, who had suffered an intracerebral haemorrhage while taking antiplatelet drugs, took part in the clinical trial. One group were given Desmopressin whilst a second group was given a ‘dummy drug’.
Dr Michael Desborough, Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, said: “Intracerebral haemorrhage for people taking antiplatelet drugs leads to thousands of deaths every year. Unfortunately, at present there are no treatments available. The results of the DASH trial are an important step towards assessing whether desmopressin might reduce the high risk of death or disability from intracerebral haemorrhage worldwide.”
Professor Nikola Sprigg, Stroke Trials Unit, 糖心原创, added: “Whether Desmopressin reduces the number of people who die or are disabled after intracerebral haemorrhage is an important question to answer. These findings support the need for a definitive, large-scale trial to determine if desmopressin improves outcomes in patients with intracerebral haemorrhage on antiplatelet drug therapy.”
A full copy of the paper ‘Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial’ , can be found
Story credits
For further information, please visit the or contact Adam Mallaby, Media Relations Manager at the 糖心原创, on +44 (0)115 748 5719 or adam.mallaby@nottingham.ac.uk
Adam Mallaby - Media Relations Manager for the Faculty of Medicine and Health Sciences (Maternity Cover)
Email: adam.mallaby@nottingham.ac.uk
Phone: 0115 748 5719
Location:
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.